Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Diseases 1 Carcinoma 1

Interventions

Cisplatin 12 pembrolizumab 11 Magnetic Resonance Spectroscopy 11 Specimen Handling 10 Paclitaxel 6 Platinum 5 Cyclophosphamide 5 1,2-diaminocyclohexaneplatinum II citrate 5 fludarabine 4 durvalumab 4 cemiplimab 4 Radiotherapy, Intensity-Modulated 4 Radiotherapy 3 Pemetrexed 3 Oxaliplatin 3 Nivolumab 3 Fluorouracil 3 Cetuximab 3 Carboplatin 3 Biopsy 3 poly ICLC 2 fludarabine phosphate 2 cabozantinib 2 atezolizumab 2 Radiation 2 Ipilimumab 2 Interviews as Topic 2 Heavy Ion Radiotherapy 2 Gemcitabine 2 Drug Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma × zipalertinib × Clear all

NCT05967689 2026-05-28

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡